Cargando…

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Curry, Joseph, Johnson, Jennifer, Tassone, Patrick, Vidal, Marina Domingo, Menezes, Diana Whitaker, Sprandio, John, Mollaee, Mehri, Cotzia, Paolo, Birbe, Ruth, Lin, Zhao, Gill, Kurren, Duddy, Elizabeth, Zhan, Tingting, Leiby, Benjamin, Reyzer, Michelle, Cognetti, David, Luginbuhl, Adam, Tuluc, Madalina, Martinez‐Outschoorn, Ubaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515672/
https://www.ncbi.nlm.nih.gov/pubmed/28185288
http://dx.doi.org/10.1002/lary.26489
_version_ 1783251018805411840
author Curry, Joseph
Johnson, Jennifer
Tassone, Patrick
Vidal, Marina Domingo
Menezes, Diana Whitaker
Sprandio, John
Mollaee, Mehri
Cotzia, Paolo
Birbe, Ruth
Lin, Zhao
Gill, Kurren
Duddy, Elizabeth
Zhan, Tingting
Leiby, Benjamin
Reyzer, Michelle
Cognetti, David
Luginbuhl, Adam
Tuluc, Madalina
Martinez‐Outschoorn, Ubaldo
author_facet Curry, Joseph
Johnson, Jennifer
Tassone, Patrick
Vidal, Marina Domingo
Menezes, Diana Whitaker
Sprandio, John
Mollaee, Mehri
Cotzia, Paolo
Birbe, Ruth
Lin, Zhao
Gill, Kurren
Duddy, Elizabeth
Zhan, Tingting
Leiby, Benjamin
Reyzer, Michelle
Cognetti, David
Luginbuhl, Adam
Tuluc, Madalina
Martinez‐Outschoorn, Ubaldo
author_sort Curry, Joseph
collection PubMed
description OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. STUDY DESIGN: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full‐treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. METHODS: Immunohistochemistry (IHC) for the metabolic markers caveolin‐1 (CAV1), B‐galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki‐67 IHC, were performed in pre‐ and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. RESULTS: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4‐fold postmetformin (P < 0.05), as measured by MSI. CONCLUSION: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1808–1815, 2017
format Online
Article
Text
id pubmed-5515672
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55156722018-08-01 Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial Curry, Joseph Johnson, Jennifer Tassone, Patrick Vidal, Marina Domingo Menezes, Diana Whitaker Sprandio, John Mollaee, Mehri Cotzia, Paolo Birbe, Ruth Lin, Zhao Gill, Kurren Duddy, Elizabeth Zhan, Tingting Leiby, Benjamin Reyzer, Michelle Cognetti, David Luginbuhl, Adam Tuluc, Madalina Martinez‐Outschoorn, Ubaldo Laryngoscope Head and Neck OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. STUDY DESIGN: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full‐treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. METHODS: Immunohistochemistry (IHC) for the metabolic markers caveolin‐1 (CAV1), B‐galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki‐67 IHC, were performed in pre‐ and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. RESULTS: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4‐fold postmetformin (P < 0.05), as measured by MSI. CONCLUSION: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1808–1815, 2017 John Wiley and Sons Inc. 2017-02-10 2017-08 /pmc/articles/PMC5515672/ /pubmed/28185288 http://dx.doi.org/10.1002/lary.26489 Text en © 2017 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Head and Neck
Curry, Joseph
Johnson, Jennifer
Tassone, Patrick
Vidal, Marina Domingo
Menezes, Diana Whitaker
Sprandio, John
Mollaee, Mehri
Cotzia, Paolo
Birbe, Ruth
Lin, Zhao
Gill, Kurren
Duddy, Elizabeth
Zhan, Tingting
Leiby, Benjamin
Reyzer, Michelle
Cognetti, David
Luginbuhl, Adam
Tuluc, Madalina
Martinez‐Outschoorn, Ubaldo
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title_full Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title_fullStr Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title_full_unstemmed Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title_short Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
title_sort metformin effects on head and neck squamous carcinoma microenvironment: window of opportunity trial
topic Head and Neck
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515672/
https://www.ncbi.nlm.nih.gov/pubmed/28185288
http://dx.doi.org/10.1002/lary.26489
work_keys_str_mv AT curryjoseph metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT johnsonjennifer metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT tassonepatrick metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT vidalmarinadomingo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT menezesdianawhitaker metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT sprandiojohn metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT mollaeemehri metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT cotziapaolo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT birberuth metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT linzhao metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT gillkurren metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT duddyelizabeth metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT zhantingting metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT leibybenjamin metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT reyzermichelle metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT cognettidavid metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT luginbuhladam metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT tulucmadalina metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial
AT martinezoutschoornubaldo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial